BIOMARIN PHARMACEUTICAL INC Investing Cash Flow
BIOMARIN PHARMACEUTICAL INC (BMRN) reported Investing Cash Flow of -$4.38 billion for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-08-06
- BIOMARIN PHARMACEUTICAL INC net cash provided by (used in) investing activities for the quarter ending 2026-06-30 was -$5.10B.
- BIOMARIN PHARMACEUTICAL INC net cash provided by (used in) investing activities for the quarter ending 2026-03-31 was $725.53M.
- BIOMARIN PHARMACEUTICAL INC net cash provided by (used in) investing activities for the quarter ending 2025-12-31 was -$42.45M, a 155.56% decline year-over-year.
- BIOMARIN PHARMACEUTICAL INC net cash provided by (used in) investing activities for the quarter ending 2025-09-30 was -$330.96M.
- BIOMARIN PHARMACEUTICAL INC net cash provided by (used in) investing activities for fiscal 2025 was -$414.24M, a 403.49% decline from fiscal 2024.
- BIOMARIN PHARMACEUTICAL INC net cash provided by (used in) investing activities for fiscal 2024 was $136.49M.
- BIOMARIN PHARMACEUTICAL INC net cash provided by (used in) investing activities for fiscal 2023 was -$111.24M.
- BIOMARIN PHARMACEUTICAL INC net cash provided by (used in) investing activities for fiscal 2022 was -$20.03M.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$5.10B derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$4.38B 10-Q · filed 2026-08-06 | -$4.42B derived: sum of 3 quarters · filed 2026-08-06 | -$4.75B derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $725.53M 10-Q · filed 2026-05-05 | $683.08M derived: sum of 2 quarters · filed 2026-05-05 | $352.12M derived: sum of 3 quarters · filed 2026-05-05 | $339.52M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$42.45M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$373.41M derived: sum of 2 quarters · filed 2026-02-26 | -$386.00M derived: sum of 3 quarters · filed 2026-08-06 | -$414.24M 10-K · filed 2026-02-26 |
| 2025-09-30 | -$330.96M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | -$343.56M derived: sum of 2 quarters · filed 2026-08-06 | -$371.79M 10-Q · filed 2025-10-28 | -$295.39M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$12.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$40.83M 10-Q · filed 2026-08-06 | $35.57M derived: sum of 3 quarters · filed 2026-08-06 | $19.42M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$28.24M 10-Q · filed 2026-05-05 | $48.17M derived: sum of 2 quarters · filed 2026-05-05 | $32.01M derived: sum of 3 quarters · filed 2026-05-05 | $122.49M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $76.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $60.25M derived: sum of 2 quarters · filed 2026-02-26 | $150.73M derived: sum of 3 quarters · filed 2026-02-26 | $136.49M 10-K · filed 2026-02-26 |
| 2024-09-30 | -$16.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | $74.32M derived: sum of 2 quarters · filed 2025-10-28 | $60.09M 10-Q · filed 2025-10-28 | -$4.88M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $90.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $76.24M 10-Q · filed 2025-08-05 | $11.28M derived: sum of 3 quarters · filed 2026-02-26 | -$34.52M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | -$14.24M 10-Q · filed 2025-05-02 | -$79.20M derived: sum of 2 quarters · filed 2026-02-26 | -$125.00M derived: sum of 3 quarters · filed 2026-02-26 | -$95.47M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | -$64.96M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$110.76M derived: sum of 2 quarters · filed 2026-02-26 | -$81.23M derived: sum of 3 quarters · filed 2026-02-26 | -$111.24M 10-K · filed 2026-02-26 |
| 2023-09-30 | -$45.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | -$16.27M derived: sum of 2 quarters · filed 2024-10-31 | -$46.28M 10-Q · filed 2024-10-31 | -$100.99M derived: sum of 4 quarters · filed 2025-02-24 |
| 2023-06-30 | $29.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-05 | -$482.00K 10-Q · filed 2024-08-05 | -$55.19M derived: sum of 3 quarters · filed 2025-02-24 | -$78.59M derived: sum of 4 quarters · filed 2025-02-24 |
| 2023-03-31 | -$30.01M 10-Q · filed 2024-04-26 | -$84.72M derived: sum of 2 quarters · filed 2025-02-24 | -$108.12M derived: sum of 3 quarters · filed 2025-02-24 | -$137.82M derived: sum of 4 quarters · filed 2025-02-24 |
| 2022-12-31 | -$54.71M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-24 | -$78.11M derived: sum of 2 quarters · filed 2025-02-24 | -$107.81M derived: sum of 3 quarters · filed 2025-02-24 | -$20.03M 10-K · filed 2025-02-24 |
| 2022-09-30 | -$23.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | -$53.10M derived: sum of 2 quarters · filed 2023-11-02 | $34.68M 10-Q · filed 2023-11-02 | -$20.74M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-06-30 | -$29.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | $58.08M 10-Q · filed 2023-08-02 | $2.66M derived: sum of 3 quarters · filed 2024-02-26 | -$117.19M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-03-31 | $87.78M 10-Q · filed 2023-04-28 | $32.36M derived: sum of 2 quarters · filed 2024-02-26 | -$87.49M derived: sum of 3 quarters · filed 2024-02-26 | -$207.74M derived: sum of 4 quarters · filed 2024-02-26 |
| 2021-12-31 | -$55.42M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | -$175.27M derived: sum of 2 quarters · filed 2024-02-26 | -$295.52M derived: sum of 3 quarters · filed 2024-02-26 | -$366.31M 10-K · filed 2024-02-26 |
| 2021-09-30 | -$119.85M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-28 | -$240.10M derived: sum of 2 quarters · filed 2022-10-28 | -$310.89M 10-Q · filed 2022-10-28 | -$299.87M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | -$120.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | -$191.04M 10-Q · filed 2022-08-04 | -$180.02M derived: sum of 3 quarters · filed 2023-02-27 | -$73.32M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | -$70.79M 10-Q · filed 2022-04-29 | -$59.76M derived: sum of 2 quarters · filed 2023-02-27 | $46.94M derived: sum of 3 quarters · filed 2023-02-27 | -$201.81M derived: sum of 4 quarters · filed 2023-02-27 |
| 2020-12-31 | $11.03M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $117.73M derived: sum of 2 quarters · filed 2023-02-27 | -$131.03M derived: sum of 3 quarters · filed 2023-02-27 | -$53.62M 10-K · filed 2023-02-27 |
| 2020-09-30 | $106.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-29 | -$142.05M derived: sum of 2 quarters · filed 2021-10-29 | -$64.65M 10-Q · filed 2021-10-29 | -$113.54M derived: sum of 4 quarters · filed 2022-02-25 |
| 2020-06-30 | -$248.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-30 | -$171.35M 10-Q · filed 2021-07-30 | -$220.24M derived: sum of 3 quarters · filed 2022-02-25 | -$171.56M derived: sum of 4 quarters · filed 2022-02-25 |
| 2020-03-31 | $77.40M 10-Q · filed 2021-04-30 | $28.51M derived: sum of 2 quarters · filed 2022-02-25 | $77.19M derived: sum of 3 quarters · filed 2022-02-25 | $96.86M derived: sum of 4 quarters · filed 2022-02-25 |
| 2019-12-31 | -$48.90M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | -$218.00K derived: sum of 2 quarters · filed 2022-02-25 | $19.45M derived: sum of 3 quarters · filed 2022-02-25 | -$31.03M 10-K · filed 2022-02-25 |
| 2019-09-30 | $48.68M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | $68.35M derived: sum of 2 quarters · filed 2020-11-06 | $17.87M 10-Q · filed 2020-11-06 | -$53.09M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-06-30 | $19.67M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | -$30.81M 10-Q · filed 2020-08-05 | -$101.77M derived: sum of 3 quarters · filed 2021-02-26 | $300.56M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-03-31 | -$50.48M 10-Q · filed 2020-05-01 | -$121.44M derived: sum of 2 quarters · filed 2021-02-26 | $280.88M derived: sum of 3 quarters · filed 2021-02-26 | $285.61M derived: sum of 4 quarters · filed 2021-02-26 |
| 2018-12-31 | -$70.96M derived: 10-K 12 month − 10-Q/A 9 month · filed 2021-02-26 | $331.36M derived: sum of 2 quarters · filed 2021-02-26 | $336.08M derived: sum of 3 quarters · filed 2021-02-26 | $264.35M 10-K · filed 2021-02-26 |
| 2018-09-30 | $402.33M derived: 10-Q/A 9 month − 10-Q 6 month · filed 2019-11-04 | $407.05M derived: sum of 2 quarters · filed 2019-11-04 | $335.31M 10-Q/A · filed 2019-11-04 | $474.86M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-06-30 | $4.72M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-02 | -$67.01M 10-Q · filed 2019-08-02 | $72.53M derived: sum of 3 quarters · filed 2020-02-27 | -$357.69M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-03-31 | -$71.73M 10-Q · filed 2019-04-29 | $67.81M derived: sum of 2 quarters · filed 2020-02-27 | -$362.42M derived: sum of 3 quarters · filed 2020-02-27 | |
| 2017-12-31 | $139.55M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | -$290.68M derived: sum of 2 quarters · filed 2020-02-27 | -$305.46M 10-K · filed 2020-02-27 | |
| 2017-09-30 | -$430.23M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-10-26 | -$445.00M 10-Q · filed 2018-10-26 | ||
| 2017-06-30 | -$14.78M 10-Q · filed 2018-08-03 | |||
| 2016-12-31 | -$484.05M 10-K · filed 2019-02-28 | |||
| 2014-03-31 | -$39.09M 10-Q · filed 2014-05-02 | -$345.51M derived: sum of 2 quarters · filed 2014-05-02 | -$342.19M derived: sum of 3 quarters · filed 2014-05-02 | -$329.94M derived: sum of 4 quarters · filed 2014-05-02 |
| 2013-12-31 | -$306.42M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-26 | -$303.10M derived: sum of 2 quarters · filed 2014-02-26 | -$290.84M derived: sum of 3 quarters · filed 2014-02-26 | -$298.78M 10-K · filed 2014-02-26 |
| 2013-09-30 | $3.31M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-10-28 | $15.57M derived: sum of 2 quarters · filed 2013-10-28 | $7.63M 10-Q · filed 2013-10-28 | -$44.72M derived: sum of 4 quarters · filed 2014-05-02 |
| 2013-06-30 | $12.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-07-29 | $4.32M 10-Q · filed 2013-07-29 | -$48.03M derived: sum of 3 quarters · filed 2014-05-02 | -$68.98M derived: sum of 4 quarters · filed 2014-05-02 |
| 2013-03-31 | -$7.94M 10-Q · filed 2014-05-02 | -$60.29M derived: sum of 2 quarters · filed 2014-05-02 | -$81.24M derived: sum of 3 quarters · filed 2014-05-02 | -$233.62M derived: sum of 4 quarters · filed 2014-05-02 |
| 2012-12-31 | -$52.35M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-26 | -$73.30M derived: sum of 2 quarters · filed 2014-02-26 | -$225.68M derived: sum of 3 quarters · filed 2014-02-26 | -$195.65M 10-K · filed 2014-02-26 |
| 2012-09-30 | -$20.95M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-10-28 | -$173.33M derived: sum of 2 quarters · filed 2013-10-28 | -$143.29M 10-Q · filed 2013-10-28 | -$178.21M derived: sum of 4 quarters · filed 2014-02-26 |
| 2012-06-30 | -$152.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-07-29 | -$122.34M 10-Q · filed 2013-07-29 | -$157.26M derived: sum of 3 quarters · filed 2014-02-26 | -$215.58M derived: sum of 4 quarters · filed 2014-02-26 |
| 2012-03-31 | $30.04M 10-Q · filed 2013-04-29 | -$4.88M derived: sum of 2 quarters · filed 2014-02-26 | -$63.20M derived: sum of 3 quarters · filed 2014-02-26 | -$62.49M derived: sum of 4 quarters · filed 2014-02-26 |
| 2011-12-31 | -$34.91M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-26 | -$93.23M derived: sum of 2 quarters · filed 2014-02-26 | -$92.53M derived: sum of 3 quarters · filed 2014-02-26 | -$89.56M 10-K · filed 2014-02-26 |
| 2011-09-30 | -$58.32M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-10-29 | -$57.62M derived: sum of 2 quarters · filed 2012-10-29 | -$54.65M 10-Q · filed 2012-10-29 | -$68.26M derived: sum of 4 quarters · filed 2013-02-26 |
| 2011-06-30 | $706.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-02 | $3.67M 10-Q · filed 2012-08-02 | -$9.94M derived: sum of 3 quarters · filed 2013-02-26 | -$13.94M derived: sum of 4 quarters · filed 2013-02-26 |
| 2011-03-31 | $2.97M 10-Q · filed 2012-04-30 | -$10.64M derived: sum of 2 quarters · filed 2013-02-26 | -$14.65M derived: sum of 3 quarters · filed 2013-02-26 | -$27.77M derived: sum of 4 quarters · filed 2013-02-26 |
| 2010-12-31 | -$13.61M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-26 | -$17.61M derived: sum of 2 quarters · filed 2013-02-26 | -$30.74M derived: sum of 3 quarters · filed 2013-02-26 | -$101.34M 10-K · filed 2013-02-26 |
| 2010-09-30 | -$4.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-10-31 | -$17.13M derived: sum of 2 quarters · filed 2011-10-31 | -$87.73M 10-Q · filed 2011-10-31 | -$133.25M derived: sum of 4 quarters · filed 2012-02-22 |
| 2010-06-30 | -$13.13M derived: 10-Q 6 month − 10-Q 3 month · filed 2011-08-01 | -$83.73M 10-Q · filed 2011-08-01 | -$129.25M derived: sum of 3 quarters · filed 2012-02-22 | -$171.47M derived: sum of 4 quarters · filed 2012-02-22 |
| 2010-03-31 | -$70.60M 10-Q · filed 2011-04-29 | -$116.12M derived: sum of 2 quarters · filed 2012-02-22 | -$158.35M derived: sum of 3 quarters · filed 2012-02-22 | |
| 2009-12-31 | -$45.52M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-22 | -$87.75M derived: sum of 2 quarters · filed 2012-02-22 | -$79.67M 10-K · filed 2012-02-22 | |
| 2009-09-30 | -$42.23M derived: 10-Q 9 month − 10-Q 6 month · filed 2010-10-29 | -$34.15M 10-Q · filed 2010-10-29 | ||
| 2009-06-30 | $8.07M 10-Q · filed 2010-08-04 | |||
| 2008-12-31 | -$19.08M 10-K · filed 2011-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |